p38 MAPK-mediated suppression of Nrf2-MPC2 axis drives metabolic reprogramming which confers imatinib resistance in blast crisis phase of chronic myeloid leukemia

Experimental Cell Research , Dec 2025

Bhat M et al. Exp Cell Res, December 2025 (epub ahead of print)

Link to full abstract